Pathological complete response in neoadjuvant treatment of breast cancer

Annals of Surgical Oncology
Patricia Cortazar, Charles E Geyer

Abstract

There has been recent interest in using pathological complete response (pCR) as a potential surrogate endpoint for long-term outcomes in the neoadjuvant treatment of high-risk, early-stage breast cancer. We review the clinical trials that have contributed to our understanding of the association between pCR and long-term outcomes, describe the various definitions of pCR, describe patient populations in which pCR may predict long-term benefit, and discuss the implications of pCR on drug development and accelerated approval for neoadjuvant treatment of breast cancer. Varying definitions of pCR across clinical trials conducted in heterogeneous patient populations make understanding the association of pCR with long-term outcomes challenging. The US Food and Drug Administration established the Collaborative Trials in Neoadjuvant Breast Cancer group to evaluate the potential use of pCR as a regulatory endpoint. The group demonstrated that pCR defined as no residual invasive cancer in the breast and axillary nodes with presence or absence of in situ cancer (ypT0/is ypN0 or ypT0 ypN0) provided a better association with improved outcomes compared to eradication of invasive tumor from the breast alone (ypT0/is). Even though pCR was not va...Continue Reading

References

Apr 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B FisherS Legault-Poisson
Mar 1, 1983·Cancer·G N HortobagyiF Schell
Jan 24, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G BonadonnaM Zambetti
Aug 15, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B FisherH D Bear
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H M KuererS E Singletary
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roman RouzierEdwige Bourstyn
Oct 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harry D BearUNKNOWN National Surgical Adjuvant Breast and Bowel Project Protocol B-27
Dec 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bryan T HennessyVicente Valero
Apr 12, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harry D BearNorman Wolmark
Jul 3, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Chafika MazouniLajos Pusztai
Sep 6, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W Fraser SymmansLajos Pusztai
Feb 6, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cornelia LiedtkeLajos Pusztai
Feb 9, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Priya RastogiNorman Wolmark
Aug 1, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F PeintingerW F Symmans
Jan 27, 2012·The New England Journal of Medicine·Harry D BearNorman Wolmark
Apr 18, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gunter von MinckwitzSibylle Loibl
Apr 9, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M M KimE A Mittendorf
Apr 10, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Luca GianniVladimir Semiglazov
Sep 11, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Laleh Amiri-KordestaniPatricia Cortazar

❮ Previous
Next ❯

Citations

Feb 10, 2016·Nature Reviews. Clinical Oncology·Frederique Penault-Llorca, Nina Radosevic-Robin
Apr 14, 2016·Breast Cancer Research and Treatment·Naoto T Ueno, Eleftherios P Mamounas
Mar 3, 2015·Annals of Surgical Oncology·Judy C Boughey, Kelly K Hunt
Sep 21, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Aditya BardiaSung-Bae Kim
Feb 23, 2019·Future Oncology·Marc ThillGary H Lyman
Dec 25, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George W Sledge
Feb 8, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A Jo ChienUNKNOWN I-SPY 2 Consortium
Nov 28, 2019·The Oncologist·Julie A SchneiderRichard Pazdur
Apr 22, 2020·American Society of Clinical Oncology Educational Book·Priyanka SharmaAlastair Thompson
Jul 14, 2020·The Breast Journal·Hirotaka MiyashitaStephen C Malamud
Jul 24, 2020·JAMA Oncology·Yu Shyr, Derek Shyr
Apr 26, 2017·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Richard MarkusPrimal Kaur
Dec 7, 2018·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·B LosadaS Del Barco
Jul 15, 2016·The New England Journal of Medicine·Hope S RugoUNKNOWN I-SPY 2 Investigators
Apr 16, 2018·Current Treatment Options in Oncology·Priyanka Sharma
Nov 6, 2020·Journal of the National Comprehensive Cancer Network : JNCCN·Bishal Gyawali, Saroj Niraula
Feb 20, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Wan Xing HongRonald Levy

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.